TestMu AI and Quarks Technosoft Partner to Power the Next Era of Autonomous Quality Engineering
14.4.2026 18:00:00 CEST | Business Wire | Press Release
TestMu AI (Formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced a strategic partnership with Quarks Technosoft, a leading digital engineering and quality consulting firm, to redefine how enterprises approach software testing in the age of AI-driven development.
As organizations increasingly adopt AI to generate code at unprecedented speed, traditional testing models are emerging as the primary constraint to innovation. This partnership brings together TestMu AI’s autonomous testing capabilities and Quarks Technosoft’s deep expertise in quality engineering transformation to create a unified, future-ready approach to software quality, one that is intelligent, scalable, and enterprise-grade.
At the core of this collaboration is a shared vision to enable Autonomous Quality Engineering, where testing evolves from a manual, reactive function into a self-governing, continuously learning system. TestMu AI delivers the intelligence layer through its agentic platform, capable of autonomously planning, authoring, and executing tests at machine speed. Quarks Technosoft complements this by embedding a human-in-the-loop strategy, helping enterprises design robust QE frameworks, integrate AI-driven workflows into CI/CD pipelines, and navigate the cultural and operational shift toward autonomous testing.
Together, the two companies are positioning themselves as a complete solution for modern software delivery, ensuring that “agentic” does not simply mean automated but truly intelligent, secure, and aligned with enterprise needs. By bridging cutting-edge AI capabilities with strategic implementation expertise, the partnership enables organizations to overcome testing bottlenecks, significantly reduce test debt, and deliver high-quality digital experiences at scale.
“As AI accelerates how software is built, the real challenge lies in ensuring quality keeps pace,” said Asad Khan, CEO & Co-Founder at TestMu AI. “Our partnership with Quarks Technosoft brings together autonomous intelligence and engineering expertise to create a self-sustaining quality layer, one that not only keeps up with development speed but fundamentally transforms how software is validated and delivered.”
Saurabh Anand, Chief of Staff, Quarks Technosoft, said, “We are entering an era where quality engineering must evolve as fast as software itself. Our partnership with TestMu AI represents a bold step toward autonomous, AI-driven quality ecosystems that redefine how enterprises build and scale digital products. By combining advanced agentic automation with Quarks’ expertise in transformation and DevSecOps, we are enabling organizations to move faster, innovate confidently, and deliver secure, high-quality experiences at scale. This collaboration is not just about improving testing; it’s about reimagining the future of software delivery.”
About TestMu AI
TestMu AI is the world’s first Agentic AI-powered Quality Engineering platform, designed to enable organizations to automate and scale testing with intelligence at its core. By combining autonomous capabilities with seamless integration across modern development workflows, TestMu AI empowers teams to deliver faster, more reliable, and secure software in an AI-first world.
For more information, visit https://www.testmuai.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20260414309669/en/
Contacts
For more information, contact
Nikhil Saxena
Press and Media Manager
9870981968
nikhils@testmuai.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF to Release First Quarter 2026 Results on May 5, 202614.4.2026 22:15:00 CEST | Press Release
IFF (NYSE: IFF) today announced that it will release its first quarter 2026 earnings results following the market close on Tuesday, May 5, 2026. The management team will host a live webcast on Wednesday, May 6, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.business
AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer14.4.2026 20:00:00 CEST | Press Release
Brenus Pharma announced that new first‑in‑human data will be presented at the AACR Annual Meeting 2026 (April 17–22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology. The poster will provide a translational overview demonstrating how STC-1010 is administrated in microsatellite‑stable colorectal cancer (MSS CRC), a setting resistant to standards immunotherapy. Clinical findings from BreAK CRC001 (NCT06934538), Phase I/IIa first‑in‑human evaluation of STC‑1010 in unresectable metastatic MSS CRC, first-line setting (n=6; median follow‑up: 6 months) show : Favorable safety with no dose‑limiting toxicities (DLTs) observed. Promising early efficacy, including 100% disease control rate (DCR) in RECIST. Evidence of immune activation, including delayed‑type hypersensitivity (DTH) responses. Exploratory analyses are ongoing to further characterize tumor–im
AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer14.4.2026 20:00:00 CEST | Press Release
Brenus Pharma announced that new first‑in‑human data will be presented at the AACR Annual Meeting 2026 (April 17–22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology. The poster will provide a translational overview demonstrating how STC-1010 is administrated in microsatellite‑stable colorectal cancer (MSS CRC), a setting resistant to standards immunotherapy. Clinical findings from BreAK CRC001 (NCT06934538), Phase I/IIa first‑in‑human evaluation of STC‑1010 in unresectable metastatic MSS CRC, first-line setting (n=6; median follow‑up: 6 months) show : Favorable safety with no dose‑limiting toxicities (DLTs) observed. Promising early efficacy, including 100% disease control rate (DCR) in RECIST. Evidence of immune activation, including delayed‑type hypersensitivity (DTH) responses. Exploratory analyses are ongoing to further characterize tumor–im
The 2026 Japan Prize Award Ceremony Is Held With Their Majesties the Emperor and Empress of Japan in Attendance14.4.2026 19:00:00 CEST | Press Release
The Japan Prize Foundation (President: Ryozo Nagai) held an award ceremony on Tuesday, April 14, at the New National Theatre, Tokyo in Tokyo's Shibuya Ward to confer the Japan Prize on scientists who have made creative and dramatic achievements in the global scientific and technological fields and who have contributed significantly to realizing peace and prosperity for all humanity. Cynthia Dwork, Ph.D. (USA), the winner in the field of Electronics, Information, and Communication, and Shizuo Akira, Ph.D. (Japan) and Zhijian “James” Chen, Ph.D. (USA), the winners in the field of Life Science, were in attendance at the award ceremony, and each field was awarded 100 million Yen together with a certificate and a medal. The winners of the 2026 Japan Prize were recommended by approximately 16,000 prominent scientists and engineers from around the world and decided by a rigorous examination taking about 1 year. The Foundation received 107 nominations for the field of Electronics, Information,
The 2026 Japan Prize Award Ceremony Is Held With Their Majesties the Emperor and Empress of Japan in Attendance14.4.2026 19:00:00 CEST | Press Release
The Japan Prize Foundation (President: Ryozo Nagai) held an award ceremony on Tuesday, April 14, at the New National Theatre, Tokyo in Tokyo's Shibuya Ward to confer the Japan Prize on scientists who have made creative and dramatic achievements in the global scientific and technological fields and who have contributed significantly to realizing peace and prosperity for all humanity. Cynthia Dwork, Ph.D. (USA), the winner in the field of Electronics, Information, and Communication, and Shizuo Akira, Ph.D. (Japan) and Zhijian “James” Chen, Ph.D. (USA), the winners in the field of Life Science, were in attendance at the award ceremony, and each field was awarded 100 million Yen together with a certificate and a medal. The winners of the 2026 Japan Prize were recommended by approximately 16,000 prominent scientists and engineers from around the world and decided by a rigorous examination taking about 1 year. The Foundation received 107 nominations for the field of Electronics, Information,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom